Parallel Advisors’s MiNK Therapeutics INKT Stock Holding History

Parallel Advisors’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1	Closed	-$11	–	3391
2023 Q3	$11	Hold	1	–	–	﹤0.01%	3336
2023 Q2	$21	Buy	+1	New	+$20	﹤0.01%	3330

Other funds holding INKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's INKT Position: Q4 2023 in Review

Parallel Advisors sold out of MiNK Therapeutics (INKT) in Q4 2023, closing a stake of 1 share — an estimated $11 sold.

Parallel Advisors first reported a position in INKT in Q2 2023 and held it in 2 quarters. The position peaked at $21 in Q2 2023. 34 funds tracked by Wall St. Rank hold INKT as of Q4 2023.

Parallel Advisors reported no remaining MiNK Therapeutics position as of Q4 2023 after selling out during the quarter.
Parallel Advisors sold 1 MiNK Therapeutics share in Q4 2023, an estimated $11.
Parallel Advisors first reported a position in MiNK Therapeutics in Q2 2023 and held it in 2 quarters.
Parallel Advisors's MiNK Therapeutics position peaked at $21 in Q2 2023.
34 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q4 2023.

Based on Parallel Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.